Sign for Notice Everyday    Sign Up| Sign In| Link| English|

Our Sponsors

    Receive Latest News

    Feedburner
    Share Us


    Conference about Risk Management for Commissioning and Qualification

    View: 222

    Website http://bit.ly/Pharmaceutical_Industry | Want to Edit it Edit Freely

    Category what is management risk process, commissioning and validation levels, Risk Analysis process

    Deadline: May 04, 2016 | Date: May 05, 2016

    Venue/Country: Online Event, U.S.A

    Updated: 2016-04-12 18:52:14 (GMT+9)

    Call For Papers - CFP

    Overview:

    As long as increase in the regulatory requirements and market needs which causes conflicts between inspectional parties and manufacturers along with limited resources for each party, there must be a harmonized baseline between two parties that both must agree on. Upon achieving this harmonization, this will minimize the efforts that will in turn increase the quality of the product.

    Risk-Bases Q&V is considered main pillar to conduct the Q&V plan mainly for the systems that could impact the product Quality (SISPQ) , and this will definitely increase the compliance awareness and decrease the cost as well.

    This course is about the technical, compliance and business benefits when conducting the Qualification and Validation (Q&V) for different systems within Pharmaceutical manufacturing facilities, and will also discuss the best Q&V Risk-based approach to minimize the efforts to have your system qualified and validated

    Areas Covered in the Session:

    Introduction to Qualification & Validation and discussion the Validation Lifecycl: This part includes introduction for the Validation including (but not limited to) what, why and when to Validate? As well as addressing the responsibilities for the validation. Also, this part will discuss the ideal LifecycSle for the systems undergoing the Q&V process so that audience will take good idea where exactly the Risk-Based can play essential role in this cycle.

    Introduction to the Risk based Q&V: During this part, there will be discussion about the risk based methodology to be used when qualification/validation new or existing systems, so that audience will take good idea about the keys of brainstorming to start implementing acceptable risk based approach prior starting the Qualification and Validation activities, upon implementing this successful and logic Risk-Based approach, this will reflect advantageous outcomes on both compliance and business wises as well.

    Case Study Discussion: Case Study will address the actual and live example that could be discussed to show how risk assessment is applied for a specific system , case study may include equipment or utilities.

    Who Will Benefit:

    Validation scientists manufacturing supervisors

    Equipment Engineers

    Engineering quality assurance specialists

    Professionals from service organizations and vendors who serve pharmaceutical clients

    Regulatory personnel involved in pharmaceutical industries.

    Pharmaceutical Project Manager

    Speaker Profile:

    Majdi Ayoub is dedicated and results-driven Q&V expert with a highly successful background with Pharmaceutical companies in both project and operation fields to achieve the best possible performance through the creation and execution of successful and creative Q&V strategies.

    Contact Detail:

    Compliance4All DBA NetZealous,

    Phone: +1-800-447-9407

    Email: supportatcompliance4All.com

    http://www.compliance4all.com/

    Event Link : http://bit.ly/Pharmaceutical_Industry

    LinkedIn Like us – https://www.linkedin.com/company/compliance4all

    Twitter Follow us – https://twitter.com/compliance4all

    Facebook Like us – https://www.facebook.com/Compliance4all


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.